よむ、つかう、まなぶ。
資料２－２ 重篤副作用疾患別対応マニュアル 骨吸収抑制薬に関する顎骨壊死・顎骨骨髄炎（案）［6.1MB］ (38 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000209243_00011.html |
| 出典情報 | 重篤副作用総合対策検討会（第16回 10／17）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
Japanese women and men with osteoporosis: results from a 1-year open-label extension of the
Denosumab Fracture Intervention Randomized Placebo Controlled Trial(DIRECT).
Osteoporos Int 2015;26:765–774.
23)Aguiar Bujanda D, Bohn Sarmiento U, et al: Assessment of renal toxicity and osteonecrosis
of the jaws in patients receiving zoledronic acid for bone metastasis. Ann Oncol. 2007;18:556–
60.
24)Brufsky AM, Sereika SM, et al: Long-term treatment with intravenous bisphosphonates in
metastatic breast cancer: a retrospective study. Breast J. 2013;19:504–511.
25)Stopeck AT, Fizazi K, et al: Safety of long-term denosumab therapy: results from the open
label extension phase of two phase 3 studies in patients with metastatic breast and prostate
cancer. Support Care Cancer. 2016;24: 447–455.
26)Chiu WY, Yang WS, et al : The influence of alendronate and tooth extraction on the
incidence of osteonecrosis of the jaw among osteoporotic subjects. PLoS One 2018;13:
e0196419.
27)Park JH, Kwoen MJ, et al : Gradual, but Not Sudden, Dose-Dependent Increase of ONJ
Risk With Bisphosphonate Exposure: A Nationwide Cohort Study in Women With
Osteoporosis. Front Endocrinol(Lausanne) 2021;12:774820.
28)Ppl Fung, Bedogni G, et al : Time to onset of bisphosphonate-related osteonecrosis of the
jaws: a multicentre retrospective cohort study. Oral Dis 2017;23:477–483.
29)Van Poznak CH, Unger JM, et al : Association of Osteonecrosis of the Jaw with Zoledronic
Acid Treatment for Bone Metastases in Patients With Cancer. JAMA Oncol 2021;7: 246–254.
30)Himelstein AL, Foster JC, et al : Effect of Longer-Interval vs Standard Dosing of
Zoledronic Acid on Skeletal Events in Patients with Bone Metastases: A Randomized Clinical
Trial. JAMA 2017;317:48–58.
31)Loyson T, Van Cann T, et al : Incidence of osteonecrosis of the jaw in patients with bone
metastases treated sequentially with bisphosphonates and denosumab. Acta Clin Belg
2018;73:100–109.
32)Everts-Graber J, Lehmann D, et al : Risk of Osteonecrosis of the Jaw Under Denosumab
Compared to Bisphosphonates in Patients With Osteoporosis. J Bone Miner Res
2022;37:340–348.
33)Higuchi T, Soga Y, et al : Replacing zoledronic acid with denosumab is a risk factor for
developing osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol
37
Denosumab Fracture Intervention Randomized Placebo Controlled Trial(DIRECT).
Osteoporos Int 2015;26:765–774.
23)Aguiar Bujanda D, Bohn Sarmiento U, et al: Assessment of renal toxicity and osteonecrosis
of the jaws in patients receiving zoledronic acid for bone metastasis. Ann Oncol. 2007;18:556–
60.
24)Brufsky AM, Sereika SM, et al: Long-term treatment with intravenous bisphosphonates in
metastatic breast cancer: a retrospective study. Breast J. 2013;19:504–511.
25)Stopeck AT, Fizazi K, et al: Safety of long-term denosumab therapy: results from the open
label extension phase of two phase 3 studies in patients with metastatic breast and prostate
cancer. Support Care Cancer. 2016;24: 447–455.
26)Chiu WY, Yang WS, et al : The influence of alendronate and tooth extraction on the
incidence of osteonecrosis of the jaw among osteoporotic subjects. PLoS One 2018;13:
e0196419.
27)Park JH, Kwoen MJ, et al : Gradual, but Not Sudden, Dose-Dependent Increase of ONJ
Risk With Bisphosphonate Exposure: A Nationwide Cohort Study in Women With
Osteoporosis. Front Endocrinol(Lausanne) 2021;12:774820.
28)Ppl Fung, Bedogni G, et al : Time to onset of bisphosphonate-related osteonecrosis of the
jaws: a multicentre retrospective cohort study. Oral Dis 2017;23:477–483.
29)Van Poznak CH, Unger JM, et al : Association of Osteonecrosis of the Jaw with Zoledronic
Acid Treatment for Bone Metastases in Patients With Cancer. JAMA Oncol 2021;7: 246–254.
30)Himelstein AL, Foster JC, et al : Effect of Longer-Interval vs Standard Dosing of
Zoledronic Acid on Skeletal Events in Patients with Bone Metastases: A Randomized Clinical
Trial. JAMA 2017;317:48–58.
31)Loyson T, Van Cann T, et al : Incidence of osteonecrosis of the jaw in patients with bone
metastases treated sequentially with bisphosphonates and denosumab. Acta Clin Belg
2018;73:100–109.
32)Everts-Graber J, Lehmann D, et al : Risk of Osteonecrosis of the Jaw Under Denosumab
Compared to Bisphosphonates in Patients With Osteoporosis. J Bone Miner Res
2022;37:340–348.
33)Higuchi T, Soga Y, et al : Replacing zoledronic acid with denosumab is a risk factor for
developing osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol
37